Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide, with adenocarcinoma being the most common histological subtype. Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that tar...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2014-09-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/650 |
| _version_ | 1819001457777573888 |
|---|---|
| author | Niki Karachaliou Rafael Rosell |
| author_facet | Niki Karachaliou Rafael Rosell |
| author_sort | Niki Karachaliou |
| collection | DOAJ |
| description | Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide, with adenocarcinoma being the most common histological subtype. Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in progression to metastatic disease and to influence response to targeted therapies. The principle goal of precision medicine is to define those patient populations most likely to respond to targeted therapies. However, the cancer genome landscape is composed of relatively few "mountains"[representing the most commonly mutated genes like KRAS, epidermal growth factor (EGFR), and anaplastic lymphoma kinase (ALK)] and a vast number of "hills" (representing low frequency but potentially actionable mutations). Low-frequency lesions that affect a druggable gene product allow a relatively small population of cancer patients for targeted therapy to be selected. |
| first_indexed | 2024-12-20T22:49:31Z |
| format | Article |
| id | doaj.art-69c8c90ebfcc4179b0ef42db81f9c0fe |
| institution | Directory Open Access Journal |
| issn | 2095-3941 2095-3941 |
| language | English |
| last_indexed | 2024-12-20T22:49:31Z |
| publishDate | 2014-09-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-69c8c90ebfcc4179b0ef42db81f9c0fe2022-12-21T19:24:16ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412095-39412014-09-0111317318110.7497/j.issn.2095-3941.2014.03.0032014030003Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyondNiki Karachaliou0Rafael Rosell1Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;Translational Research Unit, Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;Lung cancer is the most frequently diagnosed cancer and a leading cause of cancer mortality worldwide, with adenocarcinoma being the most common histological subtype. Deeper understanding of the pathobiology of non-small cell lung cancer (NSCLC) has led to the development of small molecules that target genetic mutations known to play critical roles in progression to metastatic disease and to influence response to targeted therapies. The principle goal of precision medicine is to define those patient populations most likely to respond to targeted therapies. However, the cancer genome landscape is composed of relatively few "mountains"[representing the most commonly mutated genes like KRAS, epidermal growth factor (EGFR), and anaplastic lymphoma kinase (ALK)] and a vast number of "hills" (representing low frequency but potentially actionable mutations). Low-frequency lesions that affect a druggable gene product allow a relatively small population of cancer patients for targeted therapy to be selected.http://www.cancerbiomed.org/index.php/cocr/article/view/650Lung cancerepidermal growth factor (<i>EGFR</i>)anaplastic lymphoma kinase fusions (<i>ALK</i> fusions)tyrosine kinase inhibitors (TKIs)TKI resistance |
| spellingShingle | Niki Karachaliou Rafael Rosell Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond Cancer Biology & Medicine Lung cancer epidermal growth factor (<i>EGFR</i>) anaplastic lymphoma kinase fusions (<i>ALK</i> fusions) tyrosine kinase inhibitors (TKIs) TKI resistance |
| title | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| title_full | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| title_fullStr | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| title_full_unstemmed | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| title_short | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| title_sort | systemic treatment in egfr alk nsclc patients second line therapy and beyond |
| topic | Lung cancer epidermal growth factor (<i>EGFR</i>) anaplastic lymphoma kinase fusions (<i>ALK</i> fusions) tyrosine kinase inhibitors (TKIs) TKI resistance |
| url | http://www.cancerbiomed.org/index.php/cocr/article/view/650 |
| work_keys_str_mv | AT nikikarachaliou systemictreatmentinegfralknsclcpatientssecondlinetherapyandbeyond AT rafaelrosell systemictreatmentinegfralknsclcpatientssecondlinetherapyandbeyond |